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Abstract
Background: BRAF and NRAS mutation detection is 
crucial for advanced melanoma treatment. Our aim was to 
evaluate how different characteristics from formalin-fixed 
paraffin-embedded (FFPE) samples, age of the block or 
DNA concentration could influence the success of BRAF 
and NRAS mutational screening.
Methods: DNA was obtained from 144 FFPE samples (62 
primary melanoma, 43 sentinel lymph nodes [SLN] and 39 
metastasis). BRAF and NRAS were sequenced by Sanger 
sequencing.
Results: Complete sequencing results were obtained from 
75% (108/144) of the samples, and at least one gene was 
sequenced in 89% (128/144) of them. BRAF was mutated 
in 55% (29/53) and NRAS in 11% (5/45) of the primary 
melanomas sequenced. DNA concentration correlated 
with the tumor area used for DNA extraction (mm2) (adj 
p-value < 0.01, r = 0.73). The age of the block did not affect 
sequencing success. In 60% of samples kept for more 
than 10 years, both BRAF and NRAS were successfully 
sequenced.
Conclusions: Preserving sufficient tumor area in FFPE 
blocks is important. It is necessary to keep the FFPE 
blocks, no matter their age, as they are necessary to decide 
the best treatment for the melanoma patient.
Keywords: BRAF; FFPE; melanoma; NRAS; somatic 
mutations.
Introduction
Melanoma is the most deadly of the common skin cancers. 
Melanoma mortality is around 20%, but when the tumor 
is diagnosed with a thickness exceeding 4 mm, the mor-
tality rises to 60% [1]. Targeted therapy has become one 
of the most important strategies for the treatment of meta-
static patients [2].
The MAPK-ERK pathway, which includes the RAF, 
MEK and ERK protein kinases and the small G protein RAS, 
plays an important role in melanoma development and 
progression [3]. Mutations in BRAF are found in approxi-
mately 50% of melanomas [4]. BRAF p.V600E is found in 
up to 90% of BRAF mutated tumors [5], which allowed the 
development of targeted therapies against this mutated 
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protein. BRAF-inhibitors now play an important role in 
targeted therapy in melanoma [6]. NRAS is the second 
most commonly mutated MAPK-related gene in melanoma 
tumors (13–22%) [7]. To date it has been very difficult to 
target this molecule. Furthermore, NRAS mutations can 
mediate BRAF-inhibitor resistance [8]. New primary mela-
nomas, BRAF wild type, can be developed during BRAF 
inhibition [9–12]. Thus, the detection of mutations in 
BRAF and NRAS genes in melanoma tumors is crucial to 
decide the best treatment for metastatic patients and in 
the analysis of new tumors developed during BRAF inhibi-
tion therapy.
Formalin fixation and paraffin embedding (FFPE) 
is the conventional method for preserving melanoma 
tumors [13]. We hypothesize that several characteristics of 
the block and the sample could influence the capacity to 
correctly detect BRAF and NRAS mutations in melanoma 
tumors. The aim of this project was to assess whether 
different parameters evaluated on hematoxylin-eosin 
stained slides and the age of the block, could affect DNA 
extraction and sequencing success.
Materials and methods
Patients and samples
The study initially included 165 FFPE samples belonging to 96 
melanoma patients from four groups: stage II free of relapse, stage 
II with relapse, stage III free of relapse and stage III with relapse, 
respectively (Figure 1). Melanoma subtype from pathology reports 
was available in 86% of the samples and Breslow thickness in 95% 
(Table 1). Samples were collected from January 1994 to December 
2011. The study was approved by the Ethical Committee of the Hos-
pital Clinic of Barcelona. The patients gave their written, informed 
consent.
Different parameters were evaluated on Hematoxylin-Eosin 
stained slides: the percentage of tumor present in the whole 
section, tumor cells in tumor area, immune cells in tumor area, 
stroma cells in tumor area, other cells in tumor area and total 
tumor area used for DNA extraction (mm2). According to these 
parameters, the number of sections needed per DNA extraction 
to obtain 50 mm2 of tumor area with at least 50% of tumor cells 
was estimated.
The age of the block was also recorded. All tissues had been rou-
tinely fixed in 4% buffered neutral formalin and embedded in paraf-
fin. Formalin fixation was overnight except for weekend and holidays 
Samples assessed for eligibility (n=165)
Primary tumors (n=71)
SLN (n=53)
Metastasis (n=41)
Samples available for BRAF/NRAS
mutational screening (n=144) 
Primary tumors (n=62)
SLN (n=43)
Metastasis (n=39)
Excluded samples (n=21)
Not enough tumor in block for DNA
extraction (n=5) 
DNA extraction failed (n=16)
Stage II free of relapse
Primary tumors (n=14)
Stage II to IV
Primary tumors (n=14)
Metastasis (n=18)
Stage III free of relapse
Primary tumors (n=17)
SLN (n=21)
Stage III to IV
Primary tumors (n=17)
SLN (n=22)
Metastasis (n=21)
Stage II free of relapse
Primary tumors (n=19)
Stage II to IV
Primary tumors (n=14)
Metastasis (n=18)
Stage III free of relapse
Primary tumors (n=17)
SLN (n=25)
Stage III to IV
Primary tumors (n=21)
SLN (n=28)
Metastasis (n=23)
Figure 1: Flowchart of samples included in the study.
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Table 1: Primary tumors description.
  Stage II   Stage III  
 
Total
n (%)Melanoma subtype   Free of relapse
n (%)
  With relapse
n (%)
  Free of relapse 
n (%)
  With relapse 
n (%)
SSM   13 (76%)   5 (63%)   15 (88%)   8 (42%)   41 (67%)
NM   4 (24%)   1 (12%)   2 (12%)   8 (42%)   15 (25%)
ALM   –   2 (25%)   –   1 (5%)   3 (5%)
LMM   –   –   –   1 (5%)   1 (1.5%)
Unclassifiable   –   –   –   1 (5%)   1 (1.5%)
  Mean (SD)   Mean (SD)   Mean (SD)   Mean (SD)   Mean (SD)
Breslow (mm)   3.22 (1.59)   5.4 (3.89)   1.72 (1.12)   4.31 (4.54)   3.53 (3.29)
Unknown subtype: 2 Stage II free of relapse, 6 Stage II with relapse and 2 Stage III with relapse.
SSM, superficial spreading melanoma; NM, nodular melanoma; ALM, acral lentiginous melanoma; LMM, lentigo malignant melanoma.
where fixation could last 2–3 days. FFPE samples were stored at room 
temperature.
BRAF and NRAS mutational screening
DNA extraction was performed using the QIAmp DNA FFPE Tis-
sue Kit (Qiagen, USA). DNA concentration was calculated using the 
Nanodrop (Thermo Fisher Scientific Inc., USA) absorbance measure 
method.
BRAF exons 11 and 15, and NRAS exons 2 and 3 were amplified by 
PCR using the PCR Master Mix (Promega, USA) with the primers and 
conditions described in the Supplementary Material. For samples 
that did not amplify in the first PCR, internal primers were designed 
for each exon to perform nested PCR (Supplementary Material).
The same primers were used for sequencing. The Sanger 
sequencing process was carried out by Macrogen (Macrogen Europe, 
The Netherlands) and sequences were analyzed using the SeqPilot 
Software (JSI Medical Systems GmbH, Germany). If sufficient DNA 
was available after BRAF and NRAS sequencing, a fluorescent allele-
specific PCR followed by capillary electrophoresis was performed to 
detect the BRAF p.V600E mutation, as previously described [14]. The 
sample was considered positive for p.V600E only after this variant 
was confirmed at least twice. The limitation of this study is that the 
number of repeats needed to obtain the sequence for each sample 
was not considered.
Statistical analyses
Different characteristics of the sample were evaluated according to 
sample type, age of the block ( < 5 years, 5 to 10 years,  > 10 years), 
sequencing success defined as having a sequence that could be 
clearly evaluated (both BRAF and NRAS sequenced – if at least exon 
15 of BRAF and exon 3 of NRAS were correctly sequenced it was con-
sidered successful – only one gene sequenced, neither gene success-
fully sequenced) and mutational status of the samples (BRAF/NRAS 
WT vs. mutated). Sequencing success and mutational status was also 
evaluated according to the age of the block. To compare means, non-
parametric tests (Kruskal-Wallis) were used as continuous variables 
did not follow a Normal distribution. The Pearson’s correlation and 
the two-sided Fisher’s exact test were used for continuous or cate-
gorical variables analyses, respectively. All p-values were corrected 
using the false discovery rate method (http://www.sdmproject. 
com/utilities/?show=FDR).
Results
Mutational analyses
Of the 165 total samples assessed for eligibility, DNA was 
correctly extracted in 87% (144/165), DNA extraction 
failed in 10% (16/165) and 3% (5/165) samples had not 
enough tumor in the block (Figure 1). From samples in 
which DNA extraction failed, 6/16 were primary tumors, 
9/16 SLN and 1/16 a metastasis. The age of block did not 
affect the DNA extraction success (Table 2). The median 
area used for DNA extraction was significantly smaller in 
these samples (3.8 mm) compared to the ones with DNA 
 available (6.67 mm) (adj. p = 0.01).
From the 144 samples with DNA available, BRAF 
sequencing results were obtained from 87% (125/144). 
Overall, 55% (29/53) of primary tumors sequenced, 49% 
(20/41) of SLN and 42% (13/31) of metastases had muta-
tions in BRAF. We identified the p.V600E mutation in 
98% (61/62) of mutant BRAF samples and p.V600M in 
Table 2: DNA extraction success according the age of block.
Age of block  
 
Succeeded
n (%)
 
 
Failed
n (%)
 
 
Adjusted 
p-value
 < 5 years   37 (25.7)   4 (25.0)  
5 to 10 years  73 (50.7)   9 (56.3)   1.000
 > 10 years   34 (23.6)   3 (18.8)  
Total   144 (90.0)   16 (10.0)   –
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the remaining case. We did not detect mutations in exon 
11 of BRAF. We sequenced NRAS in 80% (115/143) of all 
samples. We detected NRAS mutations in 11% (5/45) of the 
primary tumors, 12% (5/41) SLN and 14% (4/29) metasta-
sis. p.Q61R was the most frequent NRAS mutation (35.7%, 
5/14) followed by p.Q61K (28.6%, 4/14), p.Q13R (21.4%, 
3/14) and both p.Q61H and p.G60R were detected in one 
sample each.
We assessed the concordance of the mutational 
results between samples from the same patient (Figure 2). 
There was a concordance between the genetic result of the 
primary tumor and the SLN or metastasis in 77% (17/24) 
and 85% (11/13) of cases, and between SLN and metastasis 
in 44% (4/9) of cases, respectively.
We did not detect any statistically significant dif-
ferences between the different parameters assessed in 
FFPE samples according to sequencing results or age 
of the block (Table S1). The area used for DNA extrac-
tion was higher in metastasis, which also had a higher 
amount of tumor cells (adj. p < 0.01) and a higher DNA 
concentration (adj. p = 0.02), than primary tumor or 
SLN. We did not find statistically significant differences 
between the age of the block and the success of the 
sequencing process or the capacity to detect mutations 
in BRAF and NRAS (Table 3). DNA concentration cor-
related with total tissue area used for DNA extraction 
(adj. p < 0.01, r = 0.73), % of tumor in whole section (adj. 
p < 0.01, r = 0.40) and a non-significant tendency was 
observed in % of tumor cells in tumor area (adj. p = 0.06, 
r = 0.19).
Discussion
Here we have evaluated how different characteristics of 
FFPE samples, including DNA concentration, influence 
the success of mutational screening of BRAF and NRAS, 
key genes for choosing appropriate targeted therapy 
treatment in advanced melanoma. We selected 165 FFPE 
samples, including primary melanomas, SLN and metas-
tasis that were paired in some cases. DNA was obtained 
in 87% of samples. DNA extraction failure was associ-
ated with a smaller tumor area but not with the age of the 
block. Furthermore, the parameter that best correlated 
with DNA concentration was the tumor area used for DNA 
extraction. Thus, when possible, we should preserve large 
tumor areas in the FFPE blocks.
From 144 samples with DNA, BRAF was sequenced 
in 87% of samples and NRAS in 80%. The frequency of 
genomic mutations detected in primary tumors correlated 
with that previously reported [4, 15]. Shitara et al. showed 
that laser microdissection does not alter the frequency 
of BRAF and NRAS mutations [15]. We observed discord-
ances between mutations found in the primary melanoma 
and the SLN and/or the metastasis in some cases. This 
evidence has already been reported [16]. As previously 
observed [15, 17–19], in some samples we have detected 
co-occurrence of BRAF and NRAS mutations. At the single 
cell level, mutations in BRAF or NRAS are mutually exclu-
sive [17]. Supporting this hypothesis, in the paired SLN 
of a primary tumor with BRAF p.V600E and NRAS muta-
tion co-occurrence, only a NRAS mutation was detected. 
Figure 2: Genetic results by patient and samples.
The Figure shows the genetic results detected by sample type and patient to illustrate the mutation concordance between samples from the 
same individual. Patients are distributed according to the different staging groups: stage II free of relapse, stage III free of relapse, stage 
II that progressed to stage IV and stage III that progressed to stage IV. NRAS mutations detected were: p.Q13R, p.G60R, p.Q61R, p.Q61K, 
p.Q61H. *In Patient #84 different NRAS mutations were detected in the SLN and the metastasis. Patient #: Number given to each patient. 
SLN, sentinel lymph node. NA: indicates samples with no genetic results (includes samples assessed for eligibility but excluded, those in 
which the sequence could not be properly analyzed and those blocks that were not available for the study).
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It is recommended to perform the molecular screening on 
tumor tissue, preferably derived from the metastasis [20]. 
However, as BRAF inhibitors may induce metastasis in 
RAS mutant tumors [21], it would be advisable to test both 
the primary melanoma and the different metastasis tissue 
available to ensure that there are no different driver muta-
tions within samples that could influence the treatment’s 
success.
Even though more pathology colleges/societies rec-
ommend archiving FFPE tumors for at least 10 years [22–
24] or even 30 years [25], it is not regulated by law in most 
Countries. There is no single regulation that covers FFPE 
tissue specimens in the US [26] and in Spain the require-
ment is of 5 year storage after the last visit of the patient 
in the institution as part of the clinical record (Spanish 
Law 41/2002, 14th November). However, a melanoma 
patient may develop metastasis 10 or more years after 
the primary tumor diagnosis and having the FFPE speci-
men preserved could be essential for the selection of the 
most appropriate treatment. A previous study with FFPE 
samples from other solid tumors showed that macromol-
ecules could be extracted from FFPE samples, and in 
terms of quality and quantity did not differ between the 
samples archived for 1–2 years, 5–7 years or 11–12 years 
[27]. However, that study did not assess the applicability 
of those macromolecules obtained for molecular diag-
nosis. To determine whether the blocks should be kept 
for a long time for molecular diagnosis in melanoma, 
we evaluated whether the age of the block affected the 
success of the sequencing process and the capacity to 
detect mutations. Using a representative number of 
blocks with ages  < 5 years old, between 5 and 10 years or 
Table 3: Sequencing results according to the age of the block.
   < 5 years 
(n = 37)
n (%)
  5–10 years 
(n = 73)
n (%)
   > 10 years 
(n = 34)
n (%)
  Adjusted 
p-value
Sequencing success
 All genes   31 (83.8)   59 (80.8)   21 (61.8)   0.13
 One gene   4 (10.8)   5 (6.8)   8 (23.5)  
 None   2 (5.4)   9 (12.3)   5 (14.7)  
BRAF status
 WT   20 (57.1)   34 (54.0)   9 (33.3)   0.27
 mutated   15 (42.9)   29 (46.0)   18 (66.7)  
NRAS status
 WT   27 (84.4)   54 (90.0)   20 (87.0)   0.76
 mutated   5 (15.6)   6 (10.0)   3 (13.0)  
The sequencing success is defined as having a sequence that could 
be clearly evaluated. Adjusted p-values were calculated using the 
false discovery rate method.
over 10 years, we did not detect a diminished capacity 
to correctly perform the mutational screening of BRAF 
and NRAS. Although a non-significant decreased per-
centage of samples with both genes correctly sequenced 
was observed, we could obtain the sequencing results of 
NRAS and BRAF in more than 60% of samples kept for 
more than 10 years in FFPE blocks.
The optimization of the sequencing process, the exist-
ing drug combinations and the development of new drugs 
will play an important role in the future of melanoma 
therapy [28]. Some strategies have been developed to cryo-
preserve melanoma samples in bio-banking with well-
established mapping protocols using imaging techniques 
[29], but these types of strategies are not common. Thus, 
keeping the blocks for more than 10 years is useful for any 
future genetic analysis that may be required if a patient 
develops metastasis, to better determine the appropriate 
treatment.
In conclusion, it is important to preserve FFPE blocks 
in order to look for mutations that could be targeted by 
existing or new therapies. Furthermore, the age of the 
block seems not to influence mutation detection accord-
ing to the results of this study, even when they have been 
stored for more than 10 years.
Acknowledgments: Thanks to our patients and their fam-
ilies who are the main reason for our studies; to nurses 
from the Melanoma Unit of Hospital Clínic of Barcelona, 
Daniel Gabriel, Pablo Iglesias and Maria E Moliner for 
helping to collect patient data and to Helena Kruyer for 
helping with English editing and correction of the manu-
script. The work was carried out at the Esther Koplowitz 
Centre, Barcelona, Spain.
Author contributions: All the authors have accepted 
responsibility for the entire content of this submitted 
manuscript and approved submission.
Research funding: GlaxoSmithKline Biologicals SA was 
the funding source for this study. The research at the Mela-
noma Unit in Barcelona was/is partially funded by Grants 
03/0019, 05/0302, 06/0265, 09/1393 and 12/00840 from 
Fondo de Investigaciones Sanitarias, Spain; by the CIBER 
de Enfermedades Raras of the Instituto de Salud Carlos III, 
Spain; by the AGAUR 2014_SGR_603 of the Catalan Gov-
ernment, Spain; by a grant from “Fundació La Marató de 
TV3, 201331-30”, Catalonia, Spain; by the European Com-
mission under the 6th Framework Program, Contract nº: 
LSHC-CT-2006-018702 (GenoMEL) and by the National 
Cancer Institute (NCI) of the US National Institute of 
Health (NIH) (CA83115). Miriam Potrony is the recipient 
of a PhD Fellowship FI14/00231 (PFIS) from Instituto de 
Salud Carlos III, Spain.
Brought to you by | Universitat de Barcelona
Authenticated
Download Date | 4/13/17 1:37 PM
1738      Potrony et al.: BRAF/NRAS mutational screening in melanoma FFPE samples
Employment or leadership: Bénédicte Naerhuyzen and 
Nicolas Delahaye are employees of the GSK group of com-
panies. The remaining authors declare no conflicts of 
interest.
Honorarium: None declared.
Competing interests: The funding organization(s) played 
no role in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; or in the 
decision to submit the report for publication.
References
1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, 
Byrd DR, et al. Final version of 2009 AJCC melanoma staging and 
classification. J Clin Oncol 2009;2736:6199–206.
2. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 
2014;3839919:816–27.
3. Lopez-Bergami P. The role of mitogen- and stress-activated 
protein kinase pathways in melanoma. Pigment Cell Melanoma 
Res 2011;245:902–21.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, 
et al. Mutations of the BRAF gene in human cancer. Nature 
2002;4176892:949–54.
5. Flaherty KT, McArthur G. BRAF, a target in melanoma: 
implications for solid tumor drug development. Cancer 
2010;11621:4902–13.
6. Jang S, Atkins MB. Treatment of BRAF-mutant melanoma: the 
role of vemurafenib and other therapies. Clin Pharmacol Ther 
2014;951:24–31.
7. Fernandez-Medarde A, Santos E. Ras in cancer and developmen-
tal diseases. Genes Cancer 2011;23:344–58.
8. Kaplan FM, Kugel CH, 3rd, Dadpey N, Shao Y, Abel EV, Aplin 
AE. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant 
NRAS-mediated resistance to RAF inhibitor. J Biol Chem 
2012;28750:41797–807.
9. Carrera C, Puig-Butille JA, Tell-Marti G, Garcia A, Badenas C,  
Alos L, et al. Multiple BRAF wild-type melanomas during dab-
rafenib treatment for metastatic BRAF-mutant melanoma. JAMA 
Dermatol 2015;1515:544–8.
10. Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, 
Carvajal RD, et al. Atypical melanocytic proliferations and new 
primary melanomas in patients with advanced melanoma  
undergoing selective BRAF inhibition. J Clin Oncol 2012;3019: 
2375–83.
11. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma  
with BRAF V600E mutation. N Engl J Med 2011;36515:1448–9;  
author reply 50.
12. Debarbieux S, Dalle S, Depaepe L, Poulalhon N, Balme B, 
Thomas L. Second primary melanomas treated with BRAF block-
ers: study by reflectance confocal microscopy. Br J Dermatol 
2013;1686:1230–5.
13. Curry JL, Davies MA, Calderone TL, Nathanson K, Prieto VG, 
Gershenwald JE. Tissue resources for clinical use and marker 
studies in melanoma. Methods Mol Biol 2014;1102:679–95.
14. Cushman-Vokoun AM, Stover DG, Zhao Z, Koehler EA, Berlin JD, 
Vnencak-Jones CL. Clinical utility of KRAS and BRAF mutations 
in a cohort of patients with colorectal neoplasms submitted 
for microsatellite instability testing. Clin Colorectal Cancer 
2013;123:168–78.
15. Shitara D, Tell-Marti G, Badenas C, Enokihara MM, Alos L, 
Larque AB, et al. Mutational status of nevus associated- 
melanomas. Br J Dermatol 2015;173:671–80.
16. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi 
V, et al. BRAF/NRAS mutation frequencies among primary 
tumors and metastases in patients with melanoma. J Clin Oncol 
2012;3020:2522–9.
17. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, et al. 
Mutually exclusive NRASQ61R and BRAFV600E mutations at 
the single-cell level in the same human melanoma. Oncogene 
2006;2524:3357–64.
18. Chiappetta C, Proietti I, Soccodato V, Puggioni C, Zaralli R,  
Pacini L, et al. BRAF and NRAS mutations are heterogeneous  
and not mutually exclusive in nodular melanoma. Appl  
Immunohistochem Mol Morphol 2015;23:172–7.
19. Ekedahl H, Cirenajwis H, Harbst K, Carneiro A, Nielsen K, Olsson 
H, et al. The clinical significance of BRAF and NRAS mutations 
in a clinic-based metastatic melanoma cohort. Br J Dermatol 
2013;1695:1049–55.
20. Dummer R, Hauschild A, Guggenheim M, Keilholz U,  
Pentheroudakis G. Cutaneous melanoma: ESMO Clinical Practice 
Guidelines for Diagnosis, Treatment and Follow-up. Ann Oncol 
2012;23(Suppl 7):vii86–91.
21. Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G,  
Zambon A, et al. BRAF inhibitors induce metastasis in RAS 
mutant or inhibitor-resistant melanoma cells by reactivating 
MEK and ERK signaling. Sci Signal 2014;7318:ra30.
22. Sociedad española de Anatomía Patológica – International 
Academy of Pathology (SeAP-IAP). Libro Blanco de la Anatomía 
Patológica en España, 4th ed. Spain: Gráficas Dosbi, S. L., 2015.
23. Generalitat de Catalunya – Departament de Sanitat i Seguretat 
Social. Requisits que han de complir els laboratoris d’anatomia 
patològica per a la seva autorització. Barcelona: Government 
online document, 2003.
24. Comité consultatif en anatomopathologie. Guide sur l’assurance 
qualité en anatomopathologie Phases pré-analytique et 
 analytique. Quebec: Gouvernement du Québec, 2011.
25. The Royal College of Pathologists. The retention and storage of 
pathological records and specimens, 5th ed. London: The Royal 
College of Pathologists, 2015.
26. With CM, Evers DL, Mason JT. Regulatory and ethical issues on 
the utilization of FFPE tissues in research. Methods Mol Biol 
2011;724:1–21.
27. Kokkat TJ, Patel MS, McGarvey D, LiVolsi VA, Baloch ZW. 
Archived formalin-fixed paraffin-embedded (FFPE) blocks: a 
valuable underexploited resource for extraction of DNA, RNA, 
and protein. Biopreserv Biobank 2013;112:101–6.
28. Olszanski AJ. Current and future roles of targeted therapy and 
immunotherapy in advanced melanoma. J Manag Care Pharm 
2014;204:346–56.
29. Malvehy J, Aguilera P, Carrera C, Salerni G, Lovatto L, Scope A,  
et al. Ex vivo dermoscopy for biobank-oriented sampling of 
melanoma. JAMA Dermatol 2013;1499:1060–7.
Supplemental Material: The online version of this article  
(DOI: 10.1515/cclm-2015-1048) offers supplementary material, 
available to authorized users.
Brought to you by | Universitat de Barcelona
Authenticated
Download Date | 4/13/17 1:37 PM
